- Home
- MEIP vs CARM Comparison
MEIP vs CARM Comparison
Compare MEIP & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- CARM
- Stock Information
- Founded
- MEIP 2000
- CARM 2016
- Country
- MEIP United States
- CARM United States
- Employees
- MEIP N/A
- CARM N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- MEIP Health Care
- CARM Health Care
- Exchange
- MEIP Nasdaq
- CARM Nasdaq
- Market Cap
- MEIP 16.3M
- CARM 17.4M
- IPO Year
- MEIP 2003
- CARM N/A
- Fundamental
- Price
- MEIP $2.87
- CARM $0.44
- Analyst Decision
- MEIP Hold
- CARM Hold
- Analyst Count
- MEIP 2
- CARM 5
- Target Price
- MEIP $7.00
- CARM $4.57
- AVG Volume (30 Days)
- MEIP 36.2K
- CARM 277.1K
- Earning Date
- MEIP 02-11-2025
- CARM 11-07-2024
- Dividend Yield
- MEIP N/A
- CARM N/A
- EPS Growth
- MEIP N/A
- CARM N/A
- EPS
- MEIP N/A
- CARM N/A
- Revenue
- MEIP N/A
- CARM $20,268,000.00
- Revenue This Year
- MEIP N/A
- CARM $46.34
- Revenue Next Year
- MEIP $300.00
- CARM N/A
- P/E Ratio
- MEIP N/A
- CARM N/A
- Revenue Growth
- MEIP 33.76
- CARM 41.13
- 52 Week Low
- MEIP $2.30
- CARM $0.38
- 52 Week High
- MEIP $4.97
- CARM $2.77
- Technical
- Relative Strength Index (RSI)
- MEIP 66.22
- CARM 37.99
- Support Level
- MEIP $2.56
- CARM $0.42
- Resistance Level
- MEIP $2.78
- CARM $0.48
- Average True Range (ATR)
- MEIP 0.15
- CARM 0.06
- MACD
- MEIP 0.04
- CARM 0.01
- Stochastic Oscillator
- MEIP 100.00
- CARM 18.67
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.